A comparison of different modes for the detection of p53 protein accumulation. A study of bladder cancer

Pathology Research and Practice

Volumn 193, Issue 7, 1997, Pages 471-478

  Kraggerud, S M ^a   Dolven Jacobsen, K ^a   Berner, Aa ^a   Stokke, T ^a   Holm, R ^a   Smedshammer, L ^a   Borresen Dale A L ^a   Fossa S D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bladder cancer; Flow cytometry; Immunoblotting; Immunohistochemistry; p53 protein

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CANCER; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON;

EID: 9844252329     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(97)80099-4     Document Type: Article

References (33)

1. Andersen TI, Børresen A-L (1995) Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas; advantages of using CDGE in mutation detection. Diagn Mol Pathol 3: 203-211
2. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen A-L (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540-548
3. Børresen A-L (1996) Constant Denaturant Gel Electropheresis (CDGE) in Mutation Screening, in: GP Pfeifer (Ed) Technologies for detection of DNA Damage and Mutations, pp 267-279, Plenum Press, New York
4. Børresen A-L, Hovig E, Smith-Sørensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH (1991) Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natcl Acad Sci USA 88: 8405-8409
5. Børresen A-L, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D, Friend SH (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234-3236
6. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang Z-F, Rosai J, Reuter VE, Pellicer A (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-353
7. Dalbagni G, Presti JC, Reuter VE, Zhang Z-F, Sakis AS, Fair WR, Cordon-Cardo C (1993) Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in bladder cancer. Diagn Mol Pathol 2: 4-13
8. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Mcling GI, Rofstad M, Chen Y, Clausen OPFC (1993) p53 expression is associated with a high degre of tumour anaploidy and incidence of p53 gene mutation, and is localized to the aneuploid component in coloectal carcinomas. Int J Oncol 3: 305-312
9. Duffy MJ (1993) Cellular Oncogenes and Supressor Genes as Prognostic Markers in Cancer Clin Biochem 26: 439-447
10. Esrig D, Spruch CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen S-C, Skinner DG, Jonas PA, Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumour grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397
11. Greenblatt MS, Bennett WR, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
12. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Isizaki K, Fuijita J, Sugiyama T, Yoashida O (1993) Influence of Cigarette smoking and Schistosomiasis on p53 gene mutation in Urothelial Cancer. Cancer Res 53: 3795-3799
13. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. The New England Journal of Medicine 329: 1318-1327
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in Human cancer. Science 253: 49-53
15. Holm R, Skomedal H, Heiland Å, Kristensen G, Børresen A-L, Nesland JM (1993) Immunohistochemical analysis of p53 protein overexpression in normal, premalignant and malignant tissues of the cervix uteri. J Pathol 169: 21-26
16. Hsu S-M, Rainer L, Fanger HA (1981) A comparative study of the peroxidase method and an avidine-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734
17. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
18. Lane DP (1992) P53, guardian of the genome. Nature 358: 15-16
19. Lane DP (1994) The regulation of p53 function: Steiner award lecture. Int J Cancer 57: 623-627
20. Levine AJ, Chang A, Dittmer D, Notterman A, Silver A, Thorn K, Welsh D, Wu M (1994) The p53 tumor suppressor gene. J Lab Clin Med 725: 817-823
21. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
22. Lipponen PK (1993) Overexpression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53: 365-370
23. Lømo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK (1996) Expression of the BCL-2 homologue Mcl-I correlates with survival of peripheral blood B lymphocytes. Cancer Res 56: 40-43
24. Mellon K, Wilkinson S, Vickers J, Robinson MC, Shenton BK, Neal DE (1994) Abnormalities in p53 and DNA content in translational cell carcinoma of the bladder. Br J Urol 73: 522-525
25. Mørkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A, Laerum OD (1993) Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 13: 571-578
26. Mostofi FK, Sesterhenn J, Sorbin LH (1980) Histological Typing of Prostate Tumours. International histological classification of tumours. No. 22. World Health Organization, Geneva
27. Nigro JM, Baker SJ, Preisinger C, Milburn Jessup J, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707
28. Sakis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear Overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J. Natl Cancer Inst 85: 53-59
29. Serth J, Kuczyk, MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U (1995) p53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 77: 201-205
30. Smith-Sørensen B, Gebhardt MC, Kloen P, Mcintyre J, Aguilar F, Cerutti P, Børesen A-L (1993) Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat 2: 274-285
31. Thomas DJ, Robinson MC, Charlton R, Wilkerson S, Shenton BK, Neal DE (1993) p53 expression, ploidy, and progression in pT1 Translation cell carcinoma of the bladder. Br J Urol 73: 533-537
32. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887
33. Vogelstein B, Kinzler KW (1992( p53 and dysfunction. Cell 70: 523-526